Add Yahoo as a preferred source to see more of our stories on Google. A micrograph of myeloma neoplasm in a bone marrow biopsy. Johnson & Johnson’s Tecvayli helped people with multiple myeloma live ...

A micrograph of myeloma neoplasm in a bone marrow biopsy. This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive ...

Data from the MajesTEC-1 trial shows that patients with relapsed/refractory multiple myeloma responded to Tecvalyi for a median of two years and lived without disease progression for nearly a year. At ...

HORSHAM, Pa., Feb. 20, 2024 /PRNewswire/ -- Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for ...

Johnson & Johnson’s (J&J’s) two-drug combination has outperformed standard of care (SoC) for relapsed/refractory (R/R) multiple myeloma as early as second-line in a Phase III trial. During the ...

TECVAYLI® (teclistamab-cqyv) is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who ...

RARITAN, N.J., Oct. 16, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ), the worldwide leader in multiple myeloma therapies, today announced positive topline results from the investigational Phase 3 ...

Research demonstrated comparable outcomes in the real-world setting and in the phase 2 MajesTEC-1 trial when it came to treatment with Tecvayli for relapsed or refractory myeloma. Safety and efficacy ...

(RTTNews) - Johnson & Johnson (JNJ) announced new frontline data featuring TECVAYLI (teclistamab-cqyv) from two investigational studies in patients with newly diagnosed multiple myeloma (NDMM) in ...

"TECVAYLI is the only BCMA-targeted immune-based therapy with weight-based dosing. Today's approval of biweekly dosing for eligible patients will further enable clinicians to meet the individual needs ...